These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Kasono K; Blackwell JL; Douglas JT; Dmitriev I; Strong TV; Reynolds P; Kropf DA; Carroll WR; Peters GE; Bucy RP; Curiel DT; Krasnykh V Clin Cancer Res; 1999 Sep; 5(9):2571-9. PubMed ID: 10499635 [TBL] [Abstract][Full Text] [Related]
4. AdEasy-based cloning system to generate tropism expanded replicating adenoviruses expressing transgenes late in the viral life cycle. Lie-A-Ling M; Bakker CT; Wesseling JG; Bosma PJ Gene Ther; 2005 Sep; 12(17):1347-52. PubMed ID: 15877046 [TBL] [Abstract][Full Text] [Related]
5. Novel adenoviral gene delivery system targeted against head and neck cancer. Li D; Guang W; Abuzeid WM; Roy S; Gao GP; Sauk JJ; O'Malley BW Laryngoscope; 2008 Apr; 118(4):650-8. PubMed ID: 18176343 [TBL] [Abstract][Full Text] [Related]
6. Adenoviral gene therapy in head and neck cancer. Vattemi E; Claudio PP Drug News Perspect; 2006; 19(6):329-37. PubMed ID: 16971969 [TBL] [Abstract][Full Text] [Related]
7. [Gene therapy and molecular therapeutic for head and neck cancer]. Tanaka H Gan To Kagaku Ryoho; 2005 Dec; 32(13):2046-51. PubMed ID: 16352927 [TBL] [Abstract][Full Text] [Related]
8. Viral mediated gene therapy for the management of metastatic thyroid carcinoma. DeGroot LJ; Zhang R Curr Drug Targets Immune Endocr Metabol Disord; 2004 Sep; 4(3):235-44. PubMed ID: 15379725 [TBL] [Abstract][Full Text] [Related]
9. Selective replicating viral vectors : potential for use in cancer gene therapy. Nemunaitis J BioDrugs; 2003; 17(4):251-62. PubMed ID: 12899642 [TBL] [Abstract][Full Text] [Related]
10. Head and neck cancer cells are efficiently infected by Ad5/35 hybrid virus. Suominen E; Toivonen R; Grenman R; Savontaus M J Gene Med; 2006 Oct; 8(10):1223-31. PubMed ID: 16941521 [TBL] [Abstract][Full Text] [Related]
11. Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Candolfi M; Curtin JF; Xiong WD; Kroeger KM; Liu C; Rentsendorj A; Agadjanian H; Medina-Kauwe L; Palmer D; Ng P; Lowenstein PR; Castro MG Mol Ther; 2006 Sep; 14(3):371-81. PubMed ID: 16798098 [TBL] [Abstract][Full Text] [Related]
12. Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors. Nemunaitis J; Cunningham C Drug Resist Updat; 2002 Feb; 5(1):34-46. PubMed ID: 12127862 [TBL] [Abstract][Full Text] [Related]
14. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Kim M; Zinn KR; Barnett BG; Sumerel LA; Krasnykh V; Curiel DT; Douglas JT Eur J Cancer; 2002 Sep; 38(14):1917-26. PubMed ID: 12204675 [TBL] [Abstract][Full Text] [Related]
15. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. van Beusechem VW; Grill J; Mastenbroek DC; Wickham TJ; Roelvink PW; Haisma HJ; Lamfers ML; Dirven CM; Pinedo HM; Gerritsen WR J Virol; 2002 Mar; 76(6):2753-62. PubMed ID: 11861842 [TBL] [Abstract][Full Text] [Related]
16. Modified adenoviruses for cancer gene therapy. Kanerva A; Hemminki A Int J Cancer; 2004 Jul; 110(4):475-80. PubMed ID: 15122578 [TBL] [Abstract][Full Text] [Related]